Athira Pharma, Inc. (ATHA)
- Previous Close
0.2666 - Open
0.2666 - Bid 0.1860 x 200
- Ask 0.3270 x 200
- Day's Range
0.2490 - 0.2678 - 52 Week Range
0.2200 - 3.6700 - Volume
60,475 - Avg. Volume
196,098 - Market Cap (intraday)
9.928M - Beta (5Y Monthly) 3.05
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5200 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.55
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
www.athira.comRecent News: ATHA
View More
Performance Overview: ATHA
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATHA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATHA
View MoreValuation Measures
Market Cap
9.93M
Enterprise Value
-40.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.22
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.23%
Return on Equity (ttm)
-110.77%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-96.94M
Diluted EPS (ttm)
-2.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
51.27M
Total Debt/Equity (mrq)
2.71%
Levered Free Cash Flow (ttm)
-60.51M
Research Analysis: ATHA
View MoreResearch Reports: ATHA
View MoreDaily – Vickers Top Buyers & Sellers for 06/26/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/07/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/03/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/07/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.